PIPERACILLIN 4gm. IP + TAZOBACTAM 0.5gm. IP

A broad-spectrum antibacterial medicine against most gram-positive and gram-negative bacteria. (M Young, 2001) Has enhanced activity against most beta-lactamase-producing organisms. (L L Schoonover, 1995)314 Significantly more effective than ticarcillin/clavulanic acid in terms of clinical and microbiological outcomes in community-acquired pneumonia subjects. (C M Perry, 1999) More active against Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumanni than ampicillin/sulbactam, and ticarcillin/clavulanic acid. (H S Sader, 2000) Holds a good promise against gram-negative infections in burn patients. (E Mokaddas, 1998) An effective antibiotic regimen for the treatment of nosocomial infections. (R K Roland, 2000) A reliable option for the treatment of moderate-to-severe infections in hospitalized patients. (Alfred Gin, 2007) Has a useful role in the treatment of patients with polymicrobial infections caused by aerobic or anaerobic beta-lactamase-producing bacteria. (C M Perry, 1999) Demonstrates superior efficacy rates [90.5%] than ticarcillin/clavulanic acid [88.5%] for the treatment of bacterial infections. (F Hou, 1998)